Deeper Knowledge, Faster

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Deloitte
Fish and Richardson
Cipla
Chinese Patent Office
Moodys
Covington
Julphar
UBS
Farmers Insurance

Generated: January 21, 2018

DrugPatentWatch Database Preview

Details for Patent: 8,147,873

« Back to Dashboard

Summary for Patent: 8,147,873
Title:Methods and compositions for treatment of ion imbalances
Abstract: The present invention provides methods and compositions for the treatment of ion imbalances. In particular, the invention provides compositions comprising sodium-binding polymers and pharmaceutical compositions thereof. Methods of use of the polymeric and pharmaceutical compositions for therapeutic and/or prophylactic benefits are disclosed herein. Examples of these methods include the treatment of hypertension, chronic heart failure, end stage renal disease, liver cirrhosis, chronic renal insufficiency, fluid overload, or sodium overload.
Inventor(s): Charmot; Dominique (Campbell, CA), Liu; Mingjun (Campbell, CA)
Assignee: Relypsa, Inc. (Santa Clara, CA)
Application Number:12/055,457
Patent Claim Types:
see list of patent claims
Composition; Dosage form;

Drugs Protected by US Patent 8,147,873

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Relypsa Inc VELTASSA patiromer sorbitex calcium POWDER;ORAL 205739-001 Oct 21, 2015 RX Yes No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Relypsa Inc VELTASSA patiromer sorbitex calcium POWDER;ORAL 205739-002 Oct 21, 2015 RX Yes No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Relypsa Inc VELTASSA patiromer sorbitex calcium POWDER;ORAL 205739-003 Oct 21, 2015 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 8,147,873

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,854,924 Methods and compositions for treatment of ion imbalances ➤ Subscribe
8,409,561 Methods and compositions for treatment of ion imbalances ➤ Subscribe
7,429,394 Ion binding compositions ➤ Subscribe
8,282,913 Ion binding polymers and uses thereof ➤ Subscribe
8,889,115 Ion binding polymers and uses thereof ➤ Subscribe
8,778,324 Ion binding polymers and uses thereof ➤ Subscribe
8,445,014 Ion binding compositions ➤ Subscribe
8,475,780 Ion binding polymers and uses thereof ➤ Subscribe
7,488,495 Ion binding polymers and uses thereof ➤ Subscribe
8,192,758 Ion binding compositions ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 8,147,873

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria 453383 ➤ Subscribe
Austria 460927 ➤ Subscribe
Australia 2005228696 ➤ Subscribe
Australia 2005231383 ➤ Subscribe
Australia 2005231424 ➤ Subscribe
Australia 2010214729 ➤ Subscribe
Australia 2010214732 ➤ Subscribe
Australia 2012254879 ➤ Subscribe
Australia 2016216697 ➤ Subscribe
Brazil PI0509331 ➤ Subscribe
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Deloitte
Accenture
QuintilesIMS
Federal Trade Commission
McKinsey
Cipla
Chinese Patent Office
Cerilliant

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot